TIDMYGEN
Yourgene Health PLC
24 June 2019
Yourgene Health plc
("Yourgene Health" or the "Company")
Yourgene participates in key global conferences
Manchester, UK - 24 June 2019: Yourgene Health (AIM: YGEN), the
international molecular diagnostics group which commercialises
genetic products and services, announces its participation at key
conferences to raise the profile of its reproductive health
products and services.
European Society Human Genetics
Yourgene recently attended the European Human Genetics
Conference, organised by the European Society of Human Genetics.
The event - held in Gothenburg from 15-18 June 2019 - brought
together leading voices from the human genetics industry. Yourgene
hosted an exhibition stand at the event, showcasing its enlarged
product portfolio to the conference attendees, which comprised both
existing and prospective customers, distributors and partners.
For further details, please visit: https://2019.eshg.org/
18(th) World Congress in Fetal Medicine
The World Congress in Fetal Medicine will be held in Alicante,
Spain from 25-29 June 2019. The event is expected to be attended by
over 1,800 global specialists in fetal medicine. Yourgene will host
an exhibition stand at the event, showcasing the combined
reproductive health portfolio with a view to driving clinical
demand for Yourgene's NIPT service laboratory offering.
For further details, please visit:
https://fetalmedicine.org/fmf-world-congress
Canadian College of Medical Geneticists ("CCMG") Annual
Scientific Conference
The CCMG annual scientific conference is the leading industry
event in Canada, attracting leading healthcare professionals with a
focus on medical genetics. Yourgene will attend the conference to
raise the profile in Canada of its regulatory-approved reproductive
health tests.
For further details, please visit:
https://www.ccmg-ccgm.org/2019-annual-meeting.html
European Society of Human Reproduction and Embryology
("ESHRE")
From 23-26 June, ESHRE will be hosting its annual meeting in
Vienna, Austria. The principal aim of ESHRE is to promote interest
in, and understanding of, reproductive biology and medicine. Dr
Mark Street Docherty - former CEO of the recently acquired
Elucigene - will attend the event in order to promote further
understanding of the new opportunities in reproductive health.
For further details, please visit:
https://www.eshre.eu/eshre2019
The Company continues to participate in targeted events
alongside leading industry conferences. Earlier in June 2019, Dr
Stephen Little, Yourgene's Vice Chair, hosted an educational
seminar at the National Laboratory of Georgia, and Dr Robert Henke,
VP Sales, presented at an NIPT launch event in Baku,
Azerbaijan.
Lyn Rees, CEO of Yourgene Health, commented: "We are continuing
to see increased interest in our expanded portfolio of products
following the acquisition of Elucigene, and are actively seeking to
ensure existing and prospective customers and distributors are
fully aware of the range of products we now deliver in the
reproductive health space. These key industry events will enable us
to further raise awareness of our product range and enhance our
distribution networks globally."
For more information, please contact:
Yourgene Health plc Tel: +44 (0)161
Lyn Rees, Chief Executive Officer 667 1053
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
investors@yourgene-health.com
Stifel Nicolaus Europe Limited (Corporate Broker) Tel: +44 (0)20 7710
Nicholas Moore / Matthew Blawat / Ben Maddison 7600
Vigo Communications (PR) Tel: +44 (0)20 7390
Ben Simons / Fiona Henson / Antonia Pollock 0238
yourgene@vigocomms.com
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, primarily for reproductive health.
The Group's products include non-invasive prenatal tests (NIPT) for
Down's Syndrome and other genetic disorders, Cystic Fibrosis
screening tests, invasive rapid aneuploidy tests, male infertility
tests and genetic disease tests. Yourgene's commercial footprint is
already established in the UK, Europe, the Middle East, Africa and
Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene Health is also extending its
genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more information
visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABSGDLCDDBGCB
(END) Dow Jones Newswires
June 24, 2019 02:01 ET (06:01 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jul 2023 to Jul 2024